Poziotinib

Poziotinib

Legal status
Legal status	experimental
Identifiers
IUPAC name 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one
CAS Number	1092364-38-9
PubChem CID	25127713
ChemSpider	30687714
Chemical and physical data
Formula	C23H21Cl2FN4O3
Molar mass	491.34 g·mol−1
3D model (Jmol)	Interactive image
SMILES COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C
InChI InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29) Key:LPFWVDIFUFFKJU-UHFFFAOYSA-N

Poziotinib (NOV120101, HM781-36B) is a drug in development by Hanmi Pharmaceutical (in South Korea), Luye Pharma (China), and Spectrum Pharmaceuticals (rest of world) for various cancers.

It is built on an anilino-quinoline scaffold and inhibits the epidermal growth factor receptors EGRF, HER2/neu, and Her 4 and binds covalently to its targets.

It was discovered at Hanmi; in August 2014 Hanmi exclusively licensed rights in China to the Chinese company Luye Pharma and in February 2015 Hanmi licensed rights in the rest of the world outside of South Korea to Spectrum.

As of 2016 Spectrum had started a Phase II trial of poziotinib a second-line treatment for breast cancer.